• Regulatory NewsRegulatory News

    Arbitrary Pharmaceutical Price Gouging: Valeant Defends its Business Model

    As the anger over Martin Shkreli’s infamously steep and entirely arbitrary price hike of a rare disease drug has subsided, Congress has begun to turn its attention to other companies, such as Valeant Pharmaceuticals, which rely on price gouging as a foundation of their business models. On Wednesday, the Senate’s Special Committee on Aging grilled not only Valeant’s outgoing CEO, J. Michael Pearson, but its former chief financial officer, Howard Schiller, and one of the c...